Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.

Cancers (Basel) · 2022 · PMC9105283 · PMID 35565422

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendp = 0.058so close (0.05 < p ≤ 0.1)

The presence of sarcomatoid differentiation showed a trend for reduced OS (12- and 18-month OS of 52.3 and 46.4% vs. 69.0 and 59.8%, respectively, p = 0.058) 3.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.